Skip to content
10-K

Annual Report

Lexeo Therapeutics, Inc. LXEO

0001193125-26-132085

← back to feed
Filed
Mar 30, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 27, 2026 74.09M sh
Shares Diluted FY 2025 · Dec 31, 2025 53.65M sh
Shares Diluted FY 2025 · Dec 31, 2024 31.79M sh
Capex FY 2025 · Dec 31, 2025 $397K
Capex FY 2025 · Dec 31, 2024 $481K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$98.56M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$81.15M
Cash And Equivalents FY 2025 · Dec 31, 2025 $63M
Cash And Equivalents FY 2025 · Dec 31, 2024 $35.01M
Stockholders Equity FY 2025 · Dec 31, 2025 $246.67M
Stockholders Equity FY 2025 · Dec 31, 2024 $116.84M
Stockholders Equity FY 2025 · Dec 31, 2023 $113.54M
Current Liabilities FY 2025 · Dec 31, 2025 $16.81M
Current Liabilities FY 2025 · Dec 31, 2024 $22.85M
Total Liabilities FY 2025 · Dec 31, 2025 $22.02M
Total Liabilities FY 2025 · Dec 31, 2024 $30.1M
Current Assets FY 2025 · Dec 31, 2025 $188.39M
Current Assets FY 2025 · Dec 31, 2024 $126.12M
Total Assets FY 2025 · Dec 31, 2025 $268.69M
Total Assets FY 2025 · Dec 31, 2024 $146.94M
Eps Diluted FY 2025 · Dec 31, 2025 −$1.86
Eps Diluted FY 2025 · Dec 31, 2024 −$3.09
Eps Basic FY 2025 · Dec 31, 2025 −$1.86
Eps Basic FY 2025 · Dec 31, 2024 −$3.09
Sga Expense FY 2025 · Dec 31, 2025 $45.46M
Sga Expense FY 2025 · Dec 31, 2024 $31.68M
Rd Expense FY 2025 · Dec 31, 2025 $63.8M
Rd Expense FY 2025 · Dec 31, 2024 $74.09M
Net Income FY 2025 · Dec 31, 2025 −$99.96M
Net Income FY 2025 · Dec 31, 2024 −$98.33M
Operating Income FY 2025 · Dec 31, 2025 −$109.26M
Operating Income FY 2025 · Dec 31, 2024 −$105.77M